HiSiaddi is an innovative foreign trade service provider driven by both technology commercialization and foreign trade. We have established a "1+2+3+4=1" service system and can supply polypropylene glycol sourced from multiple well-known original manufacturers.
As a foreign trader with independent R&D capabilities, HiSiaddi has repeatedly proposed polypropylene glycol formula optimization schemes and application improvement recommendations through technological cooperation with manufacturers and precise market demand insight. Below is a consulting case of polypropylene glycol formula optimization by HiSiaddi.
Please contact HiSiaddi customer service for more formula optimization consulting services.
This case builds on the medical narrow-distribution PPG customization cooperation outlined in Case 1. The client, NORD-MED Biomedical of Denmark, is a listed Nordic enterprise specializing in medical polymer materials, focused on absorbable hemostatic sponges, minimally invasive wound dressings and flexible medical polyurethane film R&D and manufacturing. Its products are supplied to public hospitals and high-end medical aesthetics institutions across Nordic countries, with full production lines adhering to four strict standards: European Pharmacopoeia EP, ISO10993 medical device biocompatibility, REACH and GMP.
The client purchases 185 tons of HiSiaddi customized narrow-distribution low-precipitation medical-grade PPG2150 annually for synthesizing core medical polyurethane elastomers. After full physical and chemical testing confirmed 100% compliance of all indicators (molecular weight, hydroxyl value, acid value, moisture, metal ions, residual monomers) for the first 12 tons of domestically customized PPG, mass production replacement of original BASF imported raw materials triggered four major continuous production abnormalities: micropore foaming voids, reduced substrate tensile strength, severe batch-to-batch finished product fluctuations and slow yellowing during long-term storage.
The client’s senior formulation engineers and process technicians spent 25 days repeatedly adjusting PU polymerization temperature, NCO/OH ratio, stirring speed and curing time yet failed to eliminate production defects. Finished product yield plummeted from 98.3% with imported raw materials to 84.7%, resulting in massive semi-finished product scrap and threatening medical order delivery. The client identified the root cause as microphysical property differences between domestic and imported raw materials leading to formula incompatibility—a hidden application defect notoriously difficult to troubleshoot in high-end fine chemical manufacturing—and formally invited HiSiaddi’s technical team to conduct on-site special technical research and formula process optimization at its Danish production plant.
None of the issues stemmed from non-compliant raw material indicators. Instead, DMC-catalyzed domestic narrow-distribution PPG differs from traditional alkali-catalyzed BASF imported PPG in microstructural composition, unsaturation level, trace by-products and viscosity-temperature variation characteristics. The client’s original mature formulas were fully calibrated for imported materials and incompatible with new domestic raw materials, representing a typical high-end raw material replacement adaptability challenge.
PPG is highly hygroscopic, and domestic narrow-distribution PPG features a larger specific surface area and stronger moisture absorption than imported equivalents. The client’s original warehouse and feeding workflows lacked vacuum dehumidification steps, allowing raw materials to adsorb trace water vapor after opening. In PU polymerization systems, water reacts with isocyanates at a higher priority than PPG hydroxyl groups, generating CO₂ bubbles that form internal micropore voids post-curing. This reduces medical dressing compactness by 18% and lowers tensile breaking strength, failing medical pressure resistance standards.
DMC-catalyzed domestic PPG has lower unsaturation and more uniform end-group activity, while the client’s original formulas were calibrated for high-unsaturation BASF raw materials with curing agent and chain extender dosages matched to imported material reactivity. Switching to domestic PPG weakens overall system reactivity, resulting in insufficient crosslink density, overly flexible finished products and poor adhesion stability for medical dressings.
Domestic PPG features a molecular weight distribution coefficient ≤1.06 (far narrower than the 1.10–1.13 range of imported materials), with more ordered molecular arrangement and stable viscosity-temperature behavior. The client’s original high-temperature one-shot feeding and high-speed stirring process was optimized for wide-distribution imported PPG; when applied to narrow-distribution domestic PPG, it triggers uneven local reaction rates, causing partial over-crosslinking and partial under-crosslinking, leading to severe batch fluctuations and inconsistent product softness/hardness.
Domestic refined PPG contains trace residual unsaturated end-group impurities undetectable by routine testing, which oxidize slowly under dark long-term storage and humid conditions, causing slight yellowing of finished products after 30 days of storage—violating EU medical dressing requirements for colorless transparent appearance.
HiSiaddi dispatched a three-person specialist team consisting of a polyether synthesis engineer, medical PU formulation process engineer and polymer material stability analyst to conduct on-site research in Denmark. Through raw material component benchmarking, lab-scale trial recap, defective finished product analysis and process parameter replication, we accurately identified four fundamental root causes:
1. Domestic narrow-distribution PPG features higher purity and uniform reactivity, creating distinct reaction kinetics relative to imported materials that render original formula parameters mismatched.
2. Absence of pre-treatment workflows for PPG at the client’s facility exacerbates moisture absorption sensitivity of domestic raw materials, triggering moisture-induced side reactions.
3. Feeding, temperature rise and stirring processes optimized for legacy imported materials misalign with the steady reaction rhythm of narrow-distribution domestic PPG.
4. Original anti-oxidation and weather resistance systems formulated for impurity profiles of imported materials fail to mitigate oxidation risks from trace end-groups in domestic PPG.
HiSiaddi strictly avoided modifying the client’s core base formula ratios or replacing core raw material systems, instead delivering four minimally invasive optimizations via trace auxiliary agent fine-tuning, feeding process reconstruction, raw material pre-treatment and standardized storage to fully adapt to the physical properties of domestic customized PPG.
After 12 sets of gradient lab trials, we fine-tuned the NCO/OH equivalent ratio and slightly optimized dosages of chain extenders and medical-grade anti-oxidation additives to compensate for insufficient crosslink reactivity in the system. This fully resolved issues of inadequate crosslink density, overly soft finished products and substandard mechanical strength, perfectly matching the uniform molecular reactivity of domestic PPG.
1. Establish dedicated pre-treatment standards for medical-grade PPG: 40-minute vacuum dehydration at 75°C prior to feeding to fully remove adsorbed trace moisture.
2. Standardize raw material storage: Maintain warehouse relative humidity ≤40%; seal unused opened raw materials under nitrogen blanketing to prevent secondary moisture absorption.
3. Implement slight positive-pressure nitrogen blanketing during feeding to isolate atmospheric water vapor interference.
Abandon the client’s original "one-shot high-temperature feeding, rapid stirring" legacy process and deploy a custom tailored workflow:
1. Charge PPG base materials at low temperature (60°C) with low-speed uniform stirring for full wetting.
2. Add isocyanates via slow segmented dosing with gradient temperature rise to match the steady reaction rate of domestic PPG.
3. Supplement auxiliary agents at a constant rate mid-late reaction and cure at constant temperature to achieve synchronized uniform crosslinking across the entire system. This completely eliminates mass production defects including uneven local reactions, batch fluctuations and inconsistent softness/hardness.
Formulate a dedicated medical-grade anti-oxidation stabilization component targeted at trace unsaturated end-groups in domestic PPG. The additive does not compromise biocompatibility or alter substrate physical and chemical properties, precisely inhibiting slow end-group oxidation and permanently eliminating slight yellowing of finished products during long-term storage.
HiSiaddi delivered a complete Danish-language standardized operation manual covering raw material acceptance criteria, pre-treatment standards, feeding temperature curves, stirring parameters, curing parameters, storage specifications and fault troubleshooting guides. We conducted special training for all R&D, production and quality control personnel to enable stable independent mass production by the client.
Eight consecutive full-capacity mass production batches were verified post-implementation:
1. Complete elimination of foaming void defects: 100% compliance of substrate compactness with zero internal micropore defects, passing all medical pressure resistance and tensile testing.
2. Full recovery of mechanical performance: Tensile strength, adhesion stability and softness of finished products returned to levels matching imported raw materials; production yield rebounded from 84.7% to 98.5%.
3. Greatly improved batch consistency: Batch fluctuations in color difference, hardness and mechanical performance are fully controlled, with superior inter-batch uniformity compared to original BASF imported materials.
4. Qualified storage stability: Finished products show no yellowing or discoloration after 90-day accelerated aging testing, meeting EU medical consumable storage standards.
5. Optimized production costs: Domestic raw material localization paired with process optimization reduced scrap rates, cutting overall consumable costs by 16%.
1. The client fully eliminated concerns over adaptability of high-end domestic medical raw materials, with stable fulfillment of the annual 185-ton customized PPG framework order.
2. The client included HiSiaddi as a pre-formulation adaptability certification partner for all new medical polyurethane raw material localization replacement projects, entrusting HiSiaddi with pre-production adaptability lab trials for all new formulations.
3. Subsequent new product lines including narrow-distribution modified polyethers and ultra-low precipitation polyols were fully delegated to HiSiaddi for directional customized development.
1. The core challenge of high-end medical raw material replacement lies not in meeting indicator standards, but in formula and production process adaptability. While domestically produced refined narrow-distribution PPG offers superior purity and stability versus general imported alternatives, its distinct physical properties can disrupt production processes refined over years by clients—a technical blind spot inaccessible to ordinary commodity traders.
2. HiSiaddi’s differentiated core capability: Mastery of raw material synthesis mechanisms, downstream medical formulation expertise and mass production process optimization, delivering a closed-loop full-service system covering raw materials, formulations, production processes and long-term stability rather than simple product supply.
3. The key to retaining long-term cooperation with European and American high-end end clients is never low pricing alone, but the ability to resolve hidden technical challenges of import substitution while guaranteeing finished product yield and compliance stability.
Please contact HiSiaddi customer service for more formula optimization consulting services.
+86-13120989737 
info@hisiaddi.com 
English
